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Abstract
The global prevalence of respiratory infectious and inflammatory
diseases remains a major public health concern. Prevention and
management strategies have not kept pace with the increasing
incidence of these diseases. The airway mucosa is the most common
portal of entry for infectious and inflammatory agents. Therefore,
significant benefits would be derived from a detailed understanding
of how immune responses regulate the filigree of the airways. Here,
the role of different antigen-presenting cells (APC) in the lower
airways and the mechanisms used by pathogens to modulate APC
function during infectious disease is reviewed. Features of APC that
are unique to the airways and the influence they have on uptake
and presentation of antigen to T cells directly in the airways are
discussed. Current information on the crucial role that airway APC
play in regulating respiratory infection is summarised. We examine
the clinical implications of APC dysregulation in the airways on
asthma and tuberculosis, two chronic diseases that are the major
cause of illness and death in the developed and developing world. A
brief overview of emerging therapies that specifically target APC
function in the airways is provided.
Keywords: airway mucosal barrier, airways, antigen-presenting
cells, lung, T cells
INTRODUCTION
The prevalence of respiratory inflammatory and
infectious diseases has increased significantly over
the last few decades. The disappointing clinical
efficacy of vaccines and drugs developed to prevent
and treat respiratory diseases underscores our
limited understanding of the immunoregulatory
mechanisms of the airway microenvironment.1,2
New immunological paradigms are urgently
needed to drive vaccine development and drug
discovery for respiratory diseases. Considering its
significance, few advances have been made in our
understanding of immunity to infection of the
lower airways. The airways are exposed to a wide
variety of inhaled antigens, and therefore, the
induction of primary immunity to these antigens is
tightly controlled by professional APC such as
dendritic cells (DC) and macrophages (Table 1).3,4
Various subsets of DC and macrophages in the
airways act as ‘gate keepers’ to the lung and
become activated soon after pathogen entry.5,6
Once activated, they efficiently participate in
phagocytosis, killing, antigen transport and
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co-ordination of the innate and adaptive immune
response, the caveat being that most antigens that
reach the airway mucosal barrier (AMB) are
harmless.7 Therefore, the discriminatory powers of
the respiratory immune system are stretched to
the limit as it must separate antigenic ‘noise’ from
the rare pathogen signal. Once selected, it must
regulate the immune response to these antigens
to minimise collateral damage to the lung airways.
The airways are therefore replete with
mechanisms that prevent an inflammatory
response, such as (1) setting the ‘default’ T-cell
response to a ‘tolerance’ mode (non-inflammatory
Th2 cell-mediated immunity)
7,8; (2) induction of G0/
G1 T-cell cycle arrest
9; (3) production of iNOS or IL-
10 by alveolar macrophages (AM)10; and (4)
activation of FOXP3+ regulatory T cells (Treg),8,11
all of which play a role in suppressing T-cell
activation at the AMB. Therefore, initiation of
inflammation or an immune response requires a
combination of events that override the ‘default’
inhibitory mechanisms at the AMB.6,7 This review
focuses on the immunological processes that
regulate antigen uptake and presentation in the
lower airways. Important areas that are discussed
briefly owing to space limitations include
immunoregulatory events in lymph nodes that
drain the airways and Th2-mediated inflammatory
response leading to allergy/atopy in vivo in mice.
ANATOMICAL STRUCTURE OF THE
AIRWAYS
The airways can be divided into upper and lower
tracts.7 The upper airway consists of the nose, nasal
cavity, paranasal sinuses and the pharynx.12 The
lower airway consists of the larynx, trachea, bronchi
and bronchioles that end in tiny air sacs known as
alveoli. The trachea divides to form the right and
left bronchi that branch about 23 times to form a
pattern called the bronchial tree (Figure 1).
Passages smaller than 1 mm in diameter are called
bronchioles. Combined, the airways of the lung
have an approximate surface area of 70 m2 in
humans.7 The main function of the upper airways is
to warm, to humidify and to filter air. The lower
airways consist of a conducting zone, which forms
the respiratory passage for air, and a respiratory
zone, which is the site of gas exchange.12 This zone
is composed of the terminal bronchioles that feed
into respiratory bronchioles. The respiratory
bronchioles lead into winding alveolar ducts that
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The tracheal wall consists of several layers:
mucosa, submucosa and adventitia overlying
hyaline cartilage.12 The mucosa is composed of a
ciliated pseudostratified epithelium containing
goblet cells (detailed below) (Figure 1). Its cilia
continually propel mucus towards the pharynx.
Mucus is mainly formed of glycoproteins called
mucins.13 MUC5AC and MUC5B are the most
abundant mucins produced by the human
epithelium besides membrane-anchored mucins
such as MUC1 and MUC4. Epidermal growth factor
receptor (EGFR) plays a pivotal role in the synthesis
and secretion of mucins.13 Mucins modulate the
activity of alveolar macrophages (AM). The tissue
composition of the bronchi is similar to the
trachea.12 However, as the bronchi branch and
become smaller, the following structural changes
occur: (1) mucosal epithelium thins and changes
from pseudostratified to columnar and then to
cuboidal in the terminal bronchioles, and (2)
mucus-producing cells decrease in the bronchioles
and the amount of smooth muscle in the wall
increases, allowing bronchioles to resist air
pressure (Figure 1). Unlike the tracheal wall, the
alveolar wall consists of a single-cell lining of
respiratory epithelium composed of type-I and
type-II alveolar epithelial cells (AEC) that is
supported by a basement membrane and a sub-
epithelium containing a very rich vascular bed14
and immune cells such as DC and macrophages15
(Figure 1). The vascular bed is separated from the
overlying respiratory epithelium by a mere 0.2 µm
basement membrane, which allows for easy re-
oxygenation of blood.
Figure 1. A schematic illustrating antigen-presenting cell location and function at the AMB. The lower airways comprising the trachea, bronchus,
bronchiolus and alveolus are shown. The tracheal wall is composed of ciliated pseudostratified epithelial cells containing goblet cells. The cilia
propel mucus towards the pharynx. Mucus is formed mainly of mucins. As the trachea and the bronchus branch and become smaller, the
mucosal epithelium thins and the pseudostratified epithelium changes to columnar and then cuboidal (as illustrated). The alveolar wall consists of
AEC-I and AEC-II that is supported by a basement membrane and a sub-epithelium containing a rich bed of blood vessels and immune cells.
Epithelial barrier function is maintained by tight junctions and adherens junctions (not shown) that restrict epithelial permeability and immune cell
migration. AEC-II secrete a mixture of surfactants (shown in red). Surfactants are absent in the conducting airways which is covered by mucus
(shown in yellow), an important distinguishing feature. The alveolar space is dominated by AM whereas the interstitium is dominated by IM. The
AMB is populated by airway-resident DC that are intraepithelial and uptake antigen. Migratory DC capture and ferry antigenic cargo from the
airways to the DLN and present antigen to T cells. Secretion of cytokines and chemokines by airway epithelial cells recruits, mobilises and
activates other key immune cells such as neutrophils, eosinophils, MoDC, NK cells, Treg and Th2 cells in the submucosa (shown in the box). All of
these cells are involved in mediating an immune response against respiratory pathogens that have entered the airways and/or breached the AMB.
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ALVEOLAR MACROPHAGES
Alveolar macrophages are located almost
exclusively in the alveolar space of the lung and
play an instrumental role in lung immunity
(Figure 1).6 They express CD11chiCD11bF4/
80loMHC-IIloCD206hi (Table 1). Under steady-state
conditions, AM constitute about 90% of the total
leukocytes in the alveolar space and about 75–
80% of the total macrophage population
harvested from the bronchoalveolar lavage fluid
(BALF) of rhesus macaques and humans.3,16 AM
are specialised macrophages that play a central
role in homeostasis, tissue remodelling,
immunosurveillance and host response to
pathogens.6,17 Attempts to classify AM into
distinct subsets have led to a variety of
descriptions,18 and it is widely accepted that they
do not fit into any current macrophage
classification.6 AM play an especially important
role in the protection of the lower airways.15 AM-
ablated CD169-DTR mice infected with PR8
influenza virus show increased virus load, severe
airway inflammation, pulmonary edema and die
from the disease.19 AM are ‘quiescent’ in the
steady state, producing little inflammatory
cytokines and displaying poor phagocytic activity.6
In this state, they actively suppress both alveolar
and interstitial DC and T cells.20,21 This is
reinforced by the fact that DC recruitment and
migration to draining lymph node (DLN) are
boosted 20-fold after AM depletion.22 Similarly,
IL-13-dependent eosinophilic and Th2
inflammation is enhanced in mice depleted of AM
using clodronate liposomes.23 However, DC
suppression could be reversed by TLR stimulation
which resulted in a potent inflammatory
response.24 How do AM induce a switch between
these two opposing functions of DC (suppression
versus activation) following pathogen entry? AM
adhering to AEC in the steady state induce the
expression of avb6 integrin and TGF-b, which
suppress AM phagocytic activity.18,24 Following
TLR stimulation, TGF-b is no longer produced by
AEC, which results in AM switching to a pro-
inflammatory phenotype.
INTERSTITIAL MACROPHAGES
Interstitial macrophages (IM) are heterogeneous
macrophages that are conserved across tissues.
They are involved in tissue homeostasis and
inflammation.25 Two phenotypically distinct sub-
populations of IM, CD206+ and CD206/dim located
in the peribronchial space and alveolar
interstitium of the lung, respectively, have been
identified (Table 1).16 CD206+ and CD206 subsets
largely overlap with Lyve-1hiMHC-IIlo and Lyve-1lo
MHC-IIhi subsets described by Chakarov et al. Far
fewer in number, the phenotypic expression of
CD163, CD64 and CD11b by IM and localisation in
the perivascular space resembles that of
perivascular macrophages (PVM) that lie on the
abluminal surface of post-capillary venules and
perform crucial activities at the blood–tissue
interface.16 Detailed studies to assess whether IM
have a similar function to that of PVM have not
been conducted. However, fluorescent
Mycobacterium tuberculosis (Mtb) reporter strains
exhibited lower stress response and higher
replication in AM compared to IM.26 Further, IM
depletion increased bacterial burden suggesting
that IM are superior at controlling bacterial
growth.25 Difficulties associated with IM studies
may be related to technical limitations of lung
imaging, especially as bronchi and bronchioles are
embedded deep in the lung tissue.27 Although
lung explant imaging is a good alternative, the
mucous layer and the ‘air–liquid interface’ are
likely compromised in such in situ studies.27 In this
context, DC have been reported to project trans-
epithelial extensions into the airway lumen;
however, intravital studies were unable to observe
this phenomenon.28 Therefore, it remains unclear
whether inhaled particles are taken up by DC
localised in the bronchioles or the alveoli.29
Regardless, there is evidence that IM contributes
to AM replenishment as AM are long-lived cells
with negligible cell turnover.16 A rapid response
to infection/injury requires accelerated
recruitment of cells that have the plasticity to
transform into AM, and IM fit this description.
Further, stimulation of IM by IFN-c and LPS leads
to superior expression of TNF-a, suggesting that
IM, more than AM, form the front line of mucosal
defence in the alveoli.16
DENDRITIC CELLS
DC play an important role at the AMB in inducing
tolerance and determining the severity of
inflammatory disease (Figure 1). Using a two-
tiered nomenclature suggested by Guilliams
et al.,30,31 mouse lung DC can be divided into
three types under tier 1 – BATF3-dependent cDC1
(conventional DC1), IRF4-dependent cDC2 and E2-
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2-dependent pDC (plasmacytoid DC). A fourth
type of DC generated under inflammatory
conditions from monocytes is commonly known as
monocyte-derived DC (MoDC) (Table 1).32 Under
tier 2, the cDC subset in the lung can be further
differentiated based on the expression of CD103
or CD11b into CD11c+CD11bloCD103+ and
CD11c+CD11bhiCD103. pDC in the lung are
CD11chiMHC-IIintB220hiGr-1hi. Mouse studies have
generally used whole-lung digests, and therefore,
major differences between DC populations from
the AMB versus parenchyma have not been
appreciated. Mouse airways are dominated by
CD11chiMHC-IIhiCD11b+CD4CD8CD205+ DC, and
subsets typically seen in lymphoid tissues such as
CD8a+ DC and CD4CD8 DC are absent.33
Additionally, a small population of CD11cintMHC-
IIlo120G8pos pDC is also detected in the airways.
On the other hand, DC in the alveoli are
CD11c+CD11b+F4/80lo.34 Flow cytometric surveys
have identified several airway- and alveolar-
resident phagocytes in the BALF of healthy
humans. Besides AM, CD14+ DC and CD14 DC
(macrophage-like) and Langerin+, BDCA1+CD14+
and BDCA1+CD14 DC (DC-like) have been
identified.35 In the Itgax-YFP or CX3CR1-GFP mice
in which cDC express YFP and
monocytes/macrophages express GFP, respectively,
cDC are located near the large airways, whereas
monocytes and AM are localised in the alveolar
space.32 MoDC are located at the interface of
blood vessels and airways in MacBlue mice,
whereas pDC are located in the alveolar
interstitium. A balance between cDC and pDC in
the lung is crucial for the outcome of pulmonary
infection as Flt3L-mediated DC expansion is
compromised in pDC-depleted mice.36 Further,
depletion studies revealed that pDC-induced Treg
expansion via Sema4a-mediated pathway protects
against severe asthma.37 pDC activation also
alleviates airway hyperreactivity by increasing the
apoptotic rate of ILC2 through IFN-a production.38
Immunostaining of the rat trachea has revealed
that only 20% of total airway mucosal DC
population are found within the airway
epithelium while the remaining 80% lie beneath
the epithelium.39 Intraepithelial DC have
endocytic activity, whereas the subepithelial cells
do not. Freshly isolated airway DC are functionally
immature, MHC-IIlo, endocytosishi, mixed
lymphocyte reactionlo, IL-10hi and stimulate Th2
responses.40 They retain a somewhat ‘immature’
phenotype, even after moving to the DLN, and
this is likely to be critical for the development of
immune tolerance. Exposure of DC to thymic
stromal lymphopoietin (TSLP), TGF-b and vascular
endothelial growth factor (VEGF) or even
interaction with AM may promote this tolerogenic
phenotype. Alteration in the tolerogenic
phenotype of airway DC leads to exaggerated Th2
responses to inhaled antigens and allergic airway
inflammation.41 In line with this, conditional
depletion of airway DC by treatment of thymidine
kinase-transgenic mice with the antiviral drug
ganciclovir resulted in a significant decrease in the
number of bronchoalveolar CD4+, CD8+ T and B
lymphocytes and eosinophilic airway
inflammation.42 However, as mentioned, this topic
is beyond the scope of this review.
EPITHELIAL CELLS
Epithelial cells of the AMB are being increasingly
implicated in infectious disease pathogenesis,
although their role in asthma/allergy has been
known for some time.43 The respiratory
epithelium composed of AEC-I and AEC-II is a
physical barrier involved in modulating innate
immunity and rapid clearance of environmental
agents (Figure 1).14 AEC-II, which constitute about
7% of the total alveolar surface, secrete cytokines
and chemokines and express MHC-II constitutively
on their cell surface, a phenotype rarely exhibited
by non-professional APC.44,45 AEC-II secrete a
mixture of surfactants known as surfactant
protein A (SP-A), SP-B, SP-C and SP-D named after
their chronologic order of discovery.46 Surfactant
is formed of lipid membranes (90%) and proteins
(10%) that reduce surface tension in the alveoli.13
SP-A and SP-D are water-soluble and belong to
the family of collectins (collagenase-like lectins).
SP-B and SP-C occur in significantly smaller
amounts than SP-A. Collectins play a major role in
lung defence as shown by their capacity to
inactivate respiratory virus and gram-negative
bacteria. They modulate AM response by binding
to SIRPa, TLR4 and TLR2 receptors, enhance
phagocytosis of bacteria by acting as opsonins,
and regulate inflammation by modulating
neutrophil chemotaxis.13 Proteases produced by
AEC-II and neutrophils degrade surfactant
proteins and modulate immune cells whereas anti-
proteases produced by pathogens such as
Pseudomonas aeruginosa (Pa) elastase and Pa
protease IV counter this effect. AEC-II-derived
factors may also play an important role in
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promoting inflammation, regulating DC function
and controlling bacterial growth.44,45 AEC can
express a variety of adhesion molecules and
soluble mediators such as TGF-b, prostaglandins,
nitric oxide, TSLP and IL-10 through which they
are likely to modulate DC function within the
airway. In vitro studies have also shown that AEC-
II present mycobacterial proteins to MHC-II-
restricted CD4+ T cells.45 Why would AEC-II
present antigen to T cells when other professional
APC such as AM and DC reside in the AMB? The
answer may lie in the necessity to elicit a rapid
recall response to certain pathogens, such as
Mycobacteria. For example, the memory T-cell
response (especially the CD8+ subtype, which are
less reliant on T-cell receptor (TCR) signalling and
APC co-stimulation) is crucial for protection
against Mtb and may be stimulated by non-
professional APC.47 Of interest, AEC-II does not
express detectable levels of CD80 and CD86 and
induces tolerance to environmental antigens in
na€ıve T cells.44,45 Thus, AEC-II may be a crucial
player that affects the balance between tolerance
and inflammation in the AMB.
ANTIGEN UPTAKE IN THE AIRWAYS
DC and AM are both strategically positioned in
the airways for antigen uptake (Figure 1). They
are the predominant phagocytic populations of
the lung, in the steady state and disease.5 Studies
have shown that both DC and macrophages
extend processes into the airways for antigen
uptake, similar to DC in dermal micro-vessels and
intestinal tissue.5 Interlinked sheets of tracheal
CD103+ DC line the mucosal surface.48 These DC
associate tightly with the epithelium via the
integrin CD103 and are rarely harvested in the
BALF. Experiments using immunohistochemical
staining have positioned them on the basal side
of the epithelium wherein they express tight
junction proteins such as Claudin-1, Claudin-7 and
Zonulin.49 These molecules enable DC protrusions
to capture antigen from the airway lumen, as
shown by DC reaching across the airspace to
engulf fluorescent particles. After which, they
traffic to the DLN to elicit T-cell responses.
Two subsets of migratory cDC,
CD11c+CD11bloCD103+ and CD11c+CD11bhiCD103,
have been identified in the conducting airways of
healthy rats with a turnover rate of 2–3 days.5 They
capture and ferry antigenic cargo from the airways
to the DLN and present antigen to T cells (Figure 1).
However, in order for this to occur, antigens must
get past physical barriers such as the mucociliary
escalator, surfactants and highly phagocytic AM. In
this context, DC have been reported to acquire
antigen in the airways once a complete antigenic
saturation of AM (approx. 109 organisms) occurs.50
Once activated, AM can engulf up to 10 bacteria
each before there is a spillover to the DC
compartment.50 This may be one of many
mechanisms AM use for suppressing T-cell
responses – limiting the access of DC to pulmonary
pathogens. This is supported by studies on AM-
depleted rodents in which lung DC show enhanced
APC function and T cells acquire a pro-
inflammatory phenotype.20 Taken together, AM
are more likely to suppress antigen presentation
function rather than directly suppress T cells.22
Certain intracellular pathogens have developed
mechanisms to exploit site-specific
immunosuppression by AM to their advantage. The
immunosuppressive activity of AM may therefore
contribute to disease severity by enabling
pathogens to replicate before they are overcome
by immune cells. For example, while AM express
high levels of iNOS in Mtb-infected patients and kill
Mtb directly,51 they also suppress T-cell
activation.52 Furthermore, in the early stages of
Mtb infection in mice, the bacteria inhaled into the
respiratory airways via aerosol are taken up by AM,
which are unable to migrate to the DLN, resulting
in delayed trafficking of antigen and T-cell
activation.53 Meanwhile, Mtb burden in the lung
increases by 10 000–100 000-fold in mice leaving
the ensuing T-cell response unable to eradicate the
pathogen.54 However, T-cell responses are
efficiently induced when mycobacterial antigens of
the early secreted antigenic target 6 kda (ESAT-6)
protein family are engineered to circumvent AM
and targeted into specialised DC subsets via CD11b
or CD11c b2-integrins.
ANTIGEN PRESENTATION IN THE
AIRWAYS
After antigen acquisition, CD103+ DC traffic to the
DLN at a lower frequency than CD11bhi DC.55,56
This limitation of CD103+ DC can be offset by
their capacity to ferry larger quantities of antigen
per cell, suggesting differential capacities in these
two subsets for acquiring and presenting antigen.
Another major difference is the exclusive capacity
of CD103+ DC to acquire, transport and cross-
present apoptotic cell-associated antigen to CD8+
2020 | Vol. 9 | e1158
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T cells in the DLN.56 Thus, the primary role of
trafficking cellular, particulate and soluble
antigen from the airways to the DLN lies with the
migratory subsets of CD103+ and CD11bhi DC, but
not plasmacytoid DC, both during steady state
and infection. Once DC reach DLN, they present
antigen to CD4+ and CD8+ T cells (Figure 1).57
While CD11bhi DC present antigen via MHC-II
promoting CD4+ T-cell response, CD103+ DC cross-
present soluble antigen via MHC-I to CD8+ T
cells.57 In contrast, AM take up particulate matter
delivered intranasally but do not migrate to
DLN.22 Therefore, they are not considered to have
a role in antigen presentation in lymphoid tissue.
After stimulation by DC, naive T cells undergo
multiple rounds of cell division in the DLN and
emigrate back to the site of infection in the lung
where they can further interact with viral antigen-
displaying inflammatory DC.58 This second round
of T-cell interaction with DC in the infected lung
tissue is crucial because in vivo depletion of lung
DC leads to defective viral clearance. In this
context, CD4+CD25+FOXP3+LAG3+CTLA4+CD45RC+
Treg cells play a central role in controlling airway
DC function and allergen sensitisation in rats.59
Treg maintain immune homeostasis in the lung by
suppressing inflammation in both steady state and
infectious disease.7 In respiratory syncytial virus
(RSV)-infected mice, Treg depletion leads to
delayed viral clearance and excessive pulmonary
inflammation.60 The role of pDC in assisting Treg
homeostasis is understudied; however a recent
report points to an important role for this
interaction in the regulation of Klebsiella-
pneumonia progression.61
It is important to distinguish antigen
presentation in DLN from that occurring locally in
the lung or at the AMB. In a landmark study,
Saini et al.62 showed that local DC antigen
presentation occurs in the lung in early stages of
respiratory infection. Mice infected with a Mtb
variant (deleted for the gene PE_PGRS47) showed
enhanced MHC class II-restricted antigen
presentation by DC in all organs in vivo.
Therefore, the antigenic load at the site of
infection is critical for the timely arrival of CD8+ T
cells into the airways, and antigen availability is
also a crucial factor for CD8+ T-cell activation in
the lung.63 CD4+ T cells show increased IFN-c
production when administration of synthetic
peptides led to increased antigen presentation in
lung lesions.64 Further, an increased number of
migration-arrested, IFN-c-producing effector T
cells home into areas of the lung that have
abundant antigen. One of the earliest studies
used OVA-coated fluorescent latex beads to track
the sites and timing of antigen uptake and
presentation within the airways.65 Using this
approach, beads were detected in lung APC as
early as 2 h after intranasal injection. The data
show that antigen-loaded APC can traffic from
the airways to the lung almost immediately. This
is followed by greater numbers of transferred
OVA-specific Th1 but not Th2 or na€ıve cells
localising with bead+ APC. Based on these
observations, the authors concluded that
productive antigen/APC/T-cell interactions can
take place in the lung even before the antigen
has reached the DLN.66 Such early encounters of T
effector cells with antigen may be especially
important for the development of a robust
secondary (recall) immune response. Additionally,
studies have shown that intranasally delivered
antigens were taken up and presented to antigen-
specific T cells by CD11chi APC that remained
within lung tissues and did not migrate to
secondary lymphoid organs.66
The time-consuming process of trafficking
antigen to the DLN becomes redundant under
certain condition such as asthma, which begins
within 8 h of antigen inhalation.67 During
influenza infection for example, trans-
presentation of IL-15 directly in the lung by MHC
class I-antigen-loaded DC has the same effect as
antigen presentation to CD8+ T cells in the DLN.68
Seminal studies have suggested that antigen-
bearing DC can fast-track antigen presentation in
the airways by directly presenting antigen to T
cells in situ.29 However, the conundrum is that
only 3% of airway-resident DC project processes
between the epithelial cells, and even those never
extend past the epithelium into the airspace. On
the other hand, even though alveolar DC actively
extend and retract dendrites along the AMB to
capture antigen-loaded microspheres, antigen-
specific T cells preferentially interact with airway-
resident DC, rather than alveolar DC.29 These data
suggest that direct antigen presentation at the
AMB, if and when it occurs, is a highly regulated
process in the steady state. It appears that DC are
granted access to antigen only in the most distal
lung compartment thus restricting immune
response to the most invasive pathogen. Airways
and alveoli are therefore treated as distinct sites
by our immune system, and the differential
capacity for T-cell activation by APC may be a
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consequence of such a compartmentalisation.7
Dysregulation of these tightly controlled processes
in certain microenvironments therefore invariably
leads to disease.
LUNG NICHES
Spatially, ‘compartmentalised niches’ such as
inducible bronchus-associated lymphoid tissue
(iBALT) and nasal-associated lymphoid tissue
(NALT) also play a role in the immunity of the
respiratory tract that is distinct from that in
lymphoid or peripheral tissues.69,70 Influenza-
specific CD4+ and CD8+ resident memory T cells
are expanded and maintained long term in iBALT,
which are essentially sites of regeneration after
tissue injury.71 As T cells are replaced every
10 days in the airways, they must undergo
continual recruitment from the circulation for
their maintenance.72 How do these circulatory T
cells transition to a sessile form in the airways?
Recent data show that encounter with cognate
antigen is a key event for the conversion of
circulating to resident T cells in the lung;
however, the site or cells involved have not been
identified.69 Whether compartmentalised niches
serve as a reservoir for antigen in the airway is
unknown. It is clear however that spatial niches
are important for protection against secondary
infections by respiratory pathogens. Unlike
antigen-dependent T-cell activation in the lung,
tissue-resident memory (known as TRM) CD8
+ T
cells develop independently of cognate antigen
recognition and persist in the airways to provide
long-term protection.73 Given the intensity of
antigenic exposure in the airways, this seems
logical as T-cell activation events require strict
control at this site. This may also explain why lung
and airway TRM show distinct differences in their
repertoire and differential ability to respond to
antigen. Immune regulation may be achieved
among other mechanisms by locking memory T
cells into G0/G1 phase of the cell cycle.
THERAPEUTIC TARGETS OF APC
FUNCTION – A CLINICAL PERSPECTIVE
Asthma
Asthma is a chronic, inflammatory disease of
the airways that accounts for a significant portion
of morbidity and mortality worldwide. It is
characterised by airway hyper-responsiveness,
mucous cell hypertrophy, overproduction of
mucous and airway remodelling. A highly
heterogeneous disease asthma can be broadly
categorised into four subsets: eosinophilic,
neutrophilic, mixed granulocytic and
paucigranulocytic. DC have been implicated in the
development of asthma in both murine models
and human studies.32 There is a growing pool of
evidence demonstrating DC capacity to skew the
allergen priming of the pulmonary immune
system towards a Th2 or Th17 phenotype resulting
in eosinophilic or neutrophilic asthma,
respectively. Impaired inducible costimulatory
ligand (ICOL) expression on DC has been shown to
promote the development of aberrant Th2
responses in patients with asthma.74 Likewise,
upregulation of programmed death ligand 2 (PD-
L2) has been implicated with Th2 priming.
Blockade of PD-L2 with antibodies in vitro
resulted in decreased cytokine production,
highlighting a possible DC target for therapy.75
Another therapeutic approach may be by
manipulating the airway milieu. TSLP which is
expressed by activated lung epithelial cells
promotes Th2 responses by activating
plasmacytoid and thymic stromal lymphopoietin
protein receptor (TSLPR)+ DC.76 TSLP has been
implicated in asthma, with specific polymorphisms
being associated with an increased susceptibility
to developing the disease.77 Tezepelumab, an
anti-TSLP human monoclonal antibody, has shown
efficacy in inhibiting both early and late asthma
responses, as well as blood eosinophilia and
clinical parameters.78 This highlights the
importance of investigating the TSLP pathway
further as a target for asthma therapy. Aside from
its role in preventing IgE binding, omalizumab,
another monoclonal antibody used in the
treatment of asthma, is capable of suppressing
Th2 responses perpetuated by DC.
79 The activation
of peroxisome proliferator-activated receptor
(PPAR)-mediated pathways in DC appears to
circumvent Th2 airway inflammation through the
induction of IL-10. Rosiglitazone, a PPAR agonist
and antihyperglycaemic drug, has shown some
capacity to suppress inflammation in a subset of
asthmatic patients.80 Furthermore, Lee et al.81
have shown that rosiglitazone may be able to
prevent airway remodelling during chronic
asthma. Similarly, metformin has been associated
with decreased airway eosinophilic inflammation
in mice82 and decreased asthma exacerbations in
humans.2 Taken together, these studies and many
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others demonstrate the inextricable role DC play
in skewing airway inflammation to cause an
eosinophilic phenotype in the context of asthma.
Interestingly, AM appears to remain relatively
stable in asthma, and therefore, they have not
attracted as much attention. Nonetheless, impaired
macrophage function has been identified as a key
player in asthma. AM isolated from asthmatic
patients have a reduced capacity to phagocytose
bacteria and foreign substances such as carbon
particulate matter.83 This may allow for the altered
microbiome observed in asthmatic patients to
contribute to bacterial-induced exacerbations.
Similarly, AM isolated from patient with non-
eosinophilic asthma show impaired efferocytic
capacity (ability to clear dead or dying cells),
allowing for the accumulation of cellular debris
and neutrophils in the airways, which potentially
contributes to the chronic inflammatory state.84
Therefore, restoration of the phagocytic function
of AM may serve as an interesting target for novel
therapies. One possible avenue may be the
inhalation of GM-CSF, which has been previously
used in clinical studies to treat cystic fibrosis
patients withM. abscessus infection.85
Tuberculosis
Tuberculosis (TB) continues to be a major global
health concern. In particular, the emergence
of multidrug-resistant (MDR) and extensively
drug-resistant (XDR) Mtb strains poses an
increasing burden on health systems in many
regions of the world.86 Although new anti-
tuberculosis drugs, such as pretomanid and
bedaquiline, have shortened the lengthy
treatment regimens, particularly of MDR-TB and
XDR-TB,87,88 drug toxicity and side effects will
likely contribute to poor compliance and, hence,
future resistance development. In addition, it
remains uncertain whether any of the currently
trialled TB vaccine candidates will show
superiority over BCG and prevent pulmonary
tuberculosis in adolescents and adults.
While considerable research efforts have been
directed towards the development of new anti-TB
drugs and vaccines, the equally important area of
adjunctive host-directed therapies (HDTs) has
attracted significantly less attention.89 HDTs
enhance the immune system’s intrinsic capacity to
deal with cancerous cells or to neutralise
pathogenic bacteria, while limiting tissue
pathology. In TB, most of the current research on
HDT is focused on modulating the permissiveness
of macrophages to Mtb infection, but no current
anti-TB drug specifically targets the intracellular
AM niche.90 Due to experimental limitations in
human lung, most of our current knowledge
about the distinct functional role of individual
APC subsets, including AM, is derived from animal
studies. Nevertheless, there is increasing evidence
that human AM may also be amenable to
targeted interventions, and experiments using
human lung explants have provided critical new
insights into early responses of AM after contact
with Mtb.91 Much like in asthma, AM from
patients infected with TB have diminished
phagocytic capacity and furthermore have a
decreased ability to activate intracellular bacterial
killing pathways. This is due to Mtb modulating
phagolysosome fusion through its ESX secretion
systems, allowing for intracellular persistence and
replication.92 Several existing drugs, such as
metformin, imatinib, aspirin, pioglitazone and
alisporivir, have been shown to interfere with
recognition, uptake and/or killing of Mtb by
macrophages. The implicated host pathways in
this interference include the modulation of
autophagy, phagosomal maturation, lipid and
sugar metabolism and induction of necrosis,
among others (elegantly reviewed by Machelart et
al.90). To what extent licensed anti-TB drugs’ anti-
mycobacterial activity is augmented by host-
targeting mechanisms remains underexplored.
Another exciting aspect of HDT in TB is centred
on targeting myeloid-derived suppressor cells
(MDSCs).93 MDSCs are a heterogeneous group of
myeloid-derived monocytic and
polymorphonuclear phagocytes with strong
inhibitory potential on innate and adaptive
immune responses.94 Due to their inhibitory
potential on T cells, MDSCs have gained significant
attention in the cancer field, and it is now
appreciated that MDSCs also impair Mtb control. In
susceptible mouse strains, MDSCs also increase in
the lung in parallel with increasing TB burden,95
and in humans, MDSCs are increased in frequency
in active TB.96 As such, MDSCs constitute an
attractive HDT target in TB. Pharmacologically,
several aspects of MDSC-centred HDT have been
proposed, including reversal of the inhibitory
MDSC phenotype, depletion of MDSCs and
inhibition of MDSC recruitment.93 Trialled
compounds for these strategies include etanercept,
gefitinib, imatinib, anti-IL-6R, anti-VEGF, IDO
inhibitors, COX-2 inhibitors and calprotection.93
ª 2020 The Authors. Clinical & Translational Immunology published by John Wiley & Sons Australia, Ltd on behalf of
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Additionally, the potential to use DC-therapy as
an HDT in TB has also gained momentum. Satake
and colleagues recently demonstrated that MoDC
from TB patients could successfully be polarised
into type-1 DC, and when loaded with Mtb
antigens induced substantially stronger Mtb-
specific T-cell responses, superior activation of NK
cells and enhanced suppression of Treg compared
to standard DC.97 From a future HDT perspective,
it can be envisaged that lung-resident DC could
be targeted directly in vivo towards polarisation
into a type-1 phenotype, or alternatively, ex vivo
polarised and antigen-loaded DC could be
reinfused into the lung of TB patients.
In order to progress many of these potential
HDTs towards clinical TB application, a better
understanding of how to most efficiently deliver
compounds into the respiratory tract is required.
While nanoparticles and liposomes have been
trialled to deliver drugs directly into AM for some
time,98 biodegradable glucose polymer-based
nanoparticle approaches may prove to be more
efficient in reducing side effects and enhancing
drug delivery to the site of infection and into
specific APC cell subsets.99 Collectively, the
development of host-directed immunotherapies
that harness and optimise intrinsic antibacterial
immune mechanisms, especially in macrophages
and DC, will likely complement current antibiotic
protocols to deliver more personalised TB
treatments in the future.
FUTURE PERSPECTIVES
The confluence of cell biology and imaging has
improved the sensitivity and spatio-temporal
resolution of events that take place in the airways
and lung during infectious disease. As a
consequence, fascinating insights into the
interaction of immune cells, especially APC and
pathogens, are certain to emerge. There are
multiple APC-mediated processes that regulate T
cells at the AMB: (1) poor antigen presentation by
AM; (2) tolerogenic phenotype of DC and limited
ability to uptake antigen; and (3) non-professional
APC such as AEC-II having a tolerogenic effect on
na€ıve T cells. These biological processes have
rarely been visualised in real time in the lung, and
adopting new technologies will immensely benefit
such studies. Exploration of the ‘gut–lung axis’,
wherein the microbiome of the gut is believed to
influence susceptibility to pulmonary disease, is
also becoming a key stream of infectious diseases
research. The gut microbiome has been shown to
affect lung susceptibility to viral, fungal and
bacterial pathogens because of the common
developmental origins the digestive and
respiratory systems share. Consequently, gut–lung
crosstalk is expected to become a fertile area of
study in the future. A relatively unexplored
domain for possible novel therapeutics is naturally
occurring products derived from fauna and flora.
Such products have shown great promise in
suppressing the pathology and clinical signs
associated with inflammatory diseases and are
expected to shape future areas of study.100
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